E-ISSN 2148-5607
RELATED ARTICLES
Editorial
The immunohistochemical assessment of Ito cells in normal and experimental lier fibrosis
(Turk J Gastroenterol 1998; 9: 5-9)
Daily consensus interferon (CIFN) monotherapy in non-responders or relapsers to a previous interferon regime: One year follow-up after 48 weeks of treatment
(Turk J Gastroenterol 2006; 17: 35-39)
The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients
(Turk J Gastroenterol 2006; 17: 94-98)
Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats
(Turk J Gastroenterol 2010; 21: 287-292)
DOI: 10.4318/tjg.2010.0102
Pancreatic mass lesion mimicking carcinoma: Initial presentation of retroperitoneal fibrosis
(Turk J Gastroenterol 2005; 16: 156-159)
Predictive value of proliferating cell nuclear antigen index in response to interferon treatment in patients with chronic viral hepatitis B and C
(Turk J Gastroenterol 2001; 12: 89-94)
Relationship between histological damage, viral load and serum transaminase levels in patients with chronic hepatitis C
(Turk J Gastroenterol 2001; 12: 185-188)
Transmission routes of chronic hepatitis C and their relation to HCV genotypes
(Turk J Gastroenterol 2010; 21: 396-400)
DOI: 10.4318/tjg.2010.0126
HCV genotypes in HCV related chronic hepatitis in Southeast Anatolia
(Turk J Gastroenterol 1999; 10: 249-252)
Review
Apoptosis and fibrosis in non-alcoholic fatty liver disease
(Turk J Gastroenterol 2005; 16: 1-6)
Liver fibrosis
(Turk J Gastroenterol 2018; 29: 14-21)
DOI: 10.5152/tjg.2018.17330
Case Report
Alström syndrome with liver cirrhosis: First case from Turkey
(Turk J Gastroenterol 2013; 24: 546-548)
DOI: 10.4318/tjg.2013.0587
Chanarin-Dorfman syndrome
(Turk J Gastroenterol 2019; 30: 105-108)
DOI: 10.5152/tjg.2018.18014
Chanarin-Dorfman syndrome
(Turk J Gastroenterol ; : -)
DOI: 10.5152/tjg.2018.18014
Original Article
Clinical presentation of cystic fibrosis at the time of diagnosis: a multicenter study in a region without newborn screening
(Turk J Gastroenterol 2013; 24: 541-545)
DOI: 10.4318/tjg.2013.0653
Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients
(Turk J Gastroenterol 2012; 23: 538-545)
DOI: 10.4318/tjg.2012.0358
AST-platelet ratio index in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis B
(Turk J Gastroenterol 2012; 23: 353-358)
DOI: 10.4318/tjg.2012.0348
Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS
(Turk J Gastroenterol 2012; 23: 46-53)
DOI: 10.4318/tjg.2012.0415
AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2011; 22: 279-285)
DOI: 10.4318/tjg.2011.0213
Genotype-phenotype relationship in Iranian patients with cystic fibrosis
(Turk J Gastroenterol 2015; 26: 241-243)
DOI: 10.5152/tjg.2015.5945
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
(Turk J Gastroenterol 2016; 27: 55-61)
DOI: 10.5152/tjg.2015.150280
The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2016; 27: 156-164)
DOI: 10.5152/tjg.2015.150449
Routinely evaluated clinical assays and laboratory tests [real test] and fibrosis stages of chronic hepatitis B and C
(Turk J Gastroenterol 2014; 25: 539-545)
DOI: 10.5152/tjg.2014.6170
The association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C: An observational, multicenter study in Turkey
(Turk J Gastroenterol 2014; 25: 546-552)
DOI: 10.5152/tjg.2014.7829
Liver - Original Article
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey
(Turk J Gastroenterol 2019; 30: 331-335)
DOI: 10.5152/tjg.2018.18269
Diagnostic accuracy of glycoproteins in the assessment of liver fibrosis: A comparison between laminin, fibronectin, and hyaluronic acid
(Turk J Gastroenterol 2019; 30: 524-531)
DOI: 10.5152/tjg.2019.17339
Assessing the outcome of patients with liver cirrhosis during hospital stay: A comparison of lymphocyte/monocyte ratio with MELD and Child-Pugh scores
(Turk J Gastroenterol 2018; 29: 308-315)
DOI: 10.5152/tjg.2018.17631
Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4?
(Turk J Gastroenterol 2017; 28: 283-288)
DOI: 10.5152/tjg.2017.16640
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
(Turk J Gastroenterol 2018; 29: 464-472)
DOI: 10.5152/tjg.2018.16597
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
(Turk J Gastroenterol ; : -)
DOI: 10.5152/tjg.2018.16597
Pancreatobiliary - Original Article
Early laparoscopic cholecystectomy is associated with less risk of complications after the removal of common bile duct stones by endoscopic retrograde cholangiopancreatography
(Turk J Gastroenterol 2019; 30: 336-344)
DOI: 10.5152/tjg.2018.18272
Oral Presentation
Can advanced fibrosis be reliably excluded by simple non-invasive fibrosis scoring systems? Diagnostic performance of FIB-4 and NFS in Turkish patients with biopsy-proven non-alcoholic fatty liver disease
(Turk J Gastroenterol 2019; 30: 3-5)
DOI: 10.5152/tjg.2019.03
Poster
Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience
(Turk J Gastroenterol 2019; 30: 10-15)
DOI: 10.5152/tjg.2019.07
Validation of ELF test score for hepatic fibrosis and evaluation in turkish chronic liver disease patients
(Turk J Gastroenterol 2019; 30: 29-29)
DOI: 10.5152/tjg.2019.16
Successfully treatment of chronic hepatitis C with direct-acting antiviral agents: a single center experience
(Turk J Gastroenterol 2019; 30: 34-34)
DOI: 10.5152/tjg.2019.20
Jobert syndrome ‘’ a rare cause of liver dysfunction’’
(Turk J Gastroenterol 2019; 30: 42-42)
DOI: 10.5152/tjg.2019.27
Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection
(Turk J Gastroenterol 2019; 30: 43-45)
DOI: 10.5152/tjg.2019.28
Poster Presentation
Evaluation of diagnostic performance simple non-invasıve fibrosis markers in patients with chronic hepatitis B
(Turk J Gastroenterol 2019; 30: 100-100)
DOI: 10.5152/tjg.2019.65
Key Words
Authors
All
Reviewer's Corner
Author’s Corner
Survey
AVES | Copyright © 2019 Turkish Society of Gastroenterology | Latest Update: 04.07.2019